Drugs / Allogeneic Prostate GVAX®
Allogeneic Prostate GVAX®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00122005 | Jul 2005 | prostate cancer | Providence Health & Services | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Prostate GVAX | “The objective of this study is to evaluate the safety and immunologic effects of vaccinations with Allogeneic Prostate GVAX® (CG1940 \& CG8711) in patients made lymphopenic by...” NCT00122005 ↗ |
| Known as | CG1940 | “The objective of this study is to evaluate the safety and immunologic effects of vaccinations with Allogeneic Prostate GVAX® (CG1940 \& CG8711) in patients made lymphopenic by...” NCT00122005 ↗ |
| Known as | CG8711 | “The objective of this study is to evaluate the safety and immunologic effects of vaccinations with Allogeneic Prostate GVAX® (CG1940 \& CG8711) in patients made lymphopenic by...” NCT00122005 ↗ |
| Known as | GVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00122005 ↗ |
| Modality | Vaccine | “prostate cancer vaccines” NCT00122005 ↗ |